

Maria Kamusheva

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4492525/publications.pdf>

Version: 2024-02-01

47
papers

333
citations

932766

10
h-index

940134

16
g-index

48
all docs

48
docs citations

48
times ranked

456
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 1 | Analysis of patients' access to reimbursed biotechnological medicines for multiple sclerosis in Bulgaria and Greece. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2022, 22, 241-246. | 0.7 | 2 |
| 2 | Using real-world evidence in healthcare from Western to Central and Eastern Europe: a review of existing barriers. <i>Journal of Comparative Effectiveness Research</i> , 2022, 11, 905-913. | 0.6 | 7 |
| 3 | Influence of COVID-19 on Health-Related Quality of Life and the Perception of Being Vaccinated to Prevent COVID-19: An Approach for Community Pharmacists from Romania and Bulgaria. <i>Journal of Clinical Medicine</i> , 2021, 10, 864. | 1.0 | 14 |
| 4 | A Systematic Review of Collective Evidences Investigating the Effect of Diabetes Monitoring Systems and Their Application in Health Care. <i>Frontiers in Endocrinology</i> , 2021, 12, 636959. | 1.5 | 12 |
| 5 | Social and economic burden of breast cancer in the North East region of Bulgaria. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2021, 21, 1-7. | 0.7 | 1 |
| 6 | Pharmacotherapeutic Patterns and Patients' Access to Pharmacotherapy for Some Rare Diseases in Bulgaria – A Pilot Comparative Study. <i>Frontiers in Pharmacology</i> , 2021, 12, 695181. | 1.6 | 1 |
| 7 | Review of medicine utilization for Parkinson's disease management: the Bulgarian perspective. <i>Journal of Public Health Research</i> , 2021, , . | 0.5 | 0 |
| 8 | Do Advanced Therapies Have a Future in the Low- and Middle-Income Countries - The Case of Bulgaria, Romania, and Poland. <i>Frontiers in Public Health</i> , 2021, 9, 729847. | 1.3 | 5 |
| 9 | Pricing and Reimbursement of Patent-Protected Medicines: Challenges and Lessons from South-Eastern Europe. <i>Applied Health Economics and Health Policy</i> , 2021, 19, 915-927. | 1.0 | 5 |
| 10 | Rare disease patients' needs: an up-to-date analysis and future directions. <i>Pharmacia</i> , 2021, 68, 763-770. | 0.4 | 1 |
| 11 | Pharmacist's Perspectives on Administering a COVID-19 Vaccine in Community Pharmacies in Four Balkan Countries. <i>Frontiers in Public Health</i> , 2021, 9, 766146. | 1.3 | 8 |
| 12 | Screening for depression among chronically ill patients in community pharmacy settings: a pilot study in Bulgaria. <i>Biotechnology and Biotechnological Equipment</i> , 2021, 35, 1393-1400. | 0.5 | 1 |
| 13 | Volume and trends of adalimumab and pembrolizumab reimbursed market: the Bulgarian perspective. <i>Biotechnology and Biotechnological Equipment</i> , 2021, 35, 1778-1791. | 0.5 | 0 |
| 14 | Pharmacoeconomic analysis of pertussis booster dose in adolescents in Bulgaria. <i>Biotechnology and Biotechnological Equipment</i> , 2021, 35, 1977-1989. | 0.5 | 0 |
| 15 | Clinical and economic assessment of nusinersen: the Bulgarian perspective. <i>Expert Opinion on Orphan Drugs</i> , 2020, 8, 403-415. | 0.5 | 1 |
| 16 | Cardiovascular co-morbidity in patients with COPD in Bulgaria. <i>Biotechnology and Biotechnological Equipment</i> , 2020, 34, 918-924. | 0.5 | 1 |
| 17 | Life expectancy and survival analysis of patients with diabetes compared to the non diabetic population in Bulgaria. <i>PLoS ONE</i> , 2020, 15, e0232815. | 1.1 | 21 |
| 18 | New Epidemiological, Clinical and Economic Data for Patients With Acromegaly in Bulgaria. <i>Frontiers in Public Health</i> , 2020, 8, 147. | 1.3 | 12 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 19 | <p>The Potential Role of the Pharmacist in Supporting Patients with Depression â€“ A Literature-Based Point of View</p>. Integrated Pharmacy Research & Practice, 2020, Volume 9, 49-63. | 0.9 | 15 |
| 20 | Micro and macro analysis on the burden of COPD hospitalizations on the Bulgarian healthcare system. Biotechnology and Biotechnological Equipment, 2019, 33, 1-11. | 0.5 | 2 |
| 21 | Improved quality of diabetes control reduces complication costs in Bulgaria. Biotechnology and Biotechnological Equipment, 2019, 33, 814-820. | 0.5 | 2 |
| 22 | Chronic obstructive pulmonary disease exacerbations and progression in relation to ambient air pollutants exposure. Journal of Thoracic Disease, 2019, 11, 2490-2497. | 0.6 | 6 |
| 23 | Pilot Study on the Cost of Some Oncohematology Diseases in Bulgaria. Frontiers in Public Health, 2019, 7, 70. | 1.3 | 2 |
| 24 | Proposal for a regulation on health technology assessment in Europe â€“ opinions of policy makers, payers and academics from the field of HTA. Expert Review of Pharmacoeconomics and Outcomes Research, 2019, 19, 251-261. | 0.7 | 31 |
| 25 | Cost-effectiveness analysis of current treatment of individuals with acute exacerbation of schizophrenia in Bulgaria. Biotechnology and Biotechnological Equipment, 2019, 33, 204-213. | 0.5 | 1 |
| 26 | Incretins and SGLT-2i Therapy of Type 2 Diabetes â€“ Real Life Study of Their Therapeutic and Economic Effects. Frontiers in Pharmacology, 2019, 10, 364. | 1.6 | 0 |
| 27 | Historical overview of regulatory framework development on pricing and reimbursement of medicines in Bulgaria. Expert Review of Pharmacoeconomics and Outcomes Research, 2019, 19, 733-742. | 0.7 | 6 |
| 28 | Costs and outcomes for individuals with psychosis prior to hospital admission and following discharge in Bulgaria. Social Psychiatry and Psychiatric Epidemiology, 2019, 54, 1353-1362. | 1.6 | 5 |
| 29 | Economic and pharmaco-economic analysis of acromegaly treatment: a systematic review. Biotechnology and Biotechnological Equipment, 2019, 33, 1560-1571. | 0.5 | 2 |
| 30 | Orphan medicinal productsâ€™ access to the Bulgarian pharmaceutical market â€“ challenges and obstacles. Expert Opinion on Orphan Drugs, 2018, 6, 95-104. | 0.5 | 5 |
| 31 | The European challenges of funding orphan medicinal products. Orphanet Journal of Rare Diseases, 2018, 13, 184. | 1.2 | 34 |
| 32 | Comparative Price Analysis of Biological Products for Treatment of Rheumatoid Arthritis. Frontiers in Pharmacology, 2018, 9, 1070. | 1.6 | 30 |
| 33 | Quality of Life and Cost Study of Rheumatoid Arthritis Therapy With Biological Medicines. Frontiers in Pharmacology, 2018, 9, 794. | 1.6 | 22 |
| 34 | An Overview of the Reimbursement Decision-Making Processes in Bulgaria As a Reference Country for the Middle-Income European Countries. Frontiers in Public Health, 2018, 6, 61. | 1.3 | 4 |
| 35 | Comparative Analysis of Legislative Requirements About Patients' Access to Biotechnological Drugs for Rare Diseases in Central and Eastern European Countries. Frontiers in Pharmacology, 2018, 9, 795. | 1.6 | 13 |
| 36 | Medical, social, and economic consequences of type 2 diabetes therapy with medicinal products from the group of DPP-4i, SGLT-2i, and GLP-1 RA. International Journal of Diabetes in Developing Countries, 2018, 38, 520-521. | 0.3 | 1 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 37 | Screening and diagnosis of chronic HCV infection in Bulgaria: A review of the current practice. Biomedical Research (Aligarh, India), 2018, 29, . | 0.1 | 2 |
| 38 | A one-way, static Markov model estimating the social and economic burden of chronic obstructive pulmonary disease in Bulgaria for patients who smoke or don't. Biomedical Research (Aligarh, India), 2018, 29, . | 0.1 | 1 |
| 39 | Polycystic ovary syndrome impact on women's quality of life: pilot study. Biomedical Research (Aligarh, India), 2018, 29, . | 0.1 | 1 |
| 40 | Clinical characteristics, treatment patterns, and socio-economic burden of COPD in Bulgaria. Journal of Medical Economics, 2017, 20, 503-509. | 1.0 | 13 |
| 41 | Assessment of the expectancy, seriousness and severity of adverse drug reactions reported for chronic obstructive pulmonary disease therapy. SAGE Open Medicine, 2017, 5, 205031211769040. | 0.7 | 18 |
| 42 | Evaluation of the economic and social burden of chronic obstructive pulmonary disease (COPD). Biotechnology and Biotechnological Equipment, 2017, , 1-7. | 0.5 | 6 |
| 43 | Economic consequences of the vaccination against hepatitis A in the Bulgarian healthcare setting. Biotechnology and Biotechnological Equipment, 2014, 28, 366-371. | 0.5 | 3 |
| 44 | Budget Impact Analysis of Chronic Myeloid Leukemia Treatment in Bulgaria. Biotechnology and Biotechnological Equipment, 2013, 27, 3595-3598. | 0.5 | 3 |
| 45 | A Cross-Country Comparison of Reimbursed Orphan Medicines in Bulgaria, Greece and Romania. Biotechnology and Biotechnological Equipment, 2013, 27, 4186-4192. | 0.5 | 9 |
| 46 | A HEALTH-RELATED QUALITY OF LIFE AND PHARMACOTHERAPY COSTS STUDY FOR PATIENTS WITH CYSTIC FIBROSIS, GAUCHER DISEASE AND CHRONIC MYELOID LEUKEMIA IN BULGARIA. Biotechnology and Biotechnological Equipment, 2013, 27, 3896-3900. | 0.5 | 2 |
| 47 | The Health Related Quality of Life for Kidney Transplant Patients in Bulgaria – A Pilot Study. Biotechnology and Biotechnological Equipment, 2012, 26, 3062-3065. | 0.5 | 2 |